Key information

🔎 Fund Overview

Silverback Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The Company’s lead virology product candidate, SBT8230, is an ASGR1-TLR8 ImmunoTAC therapeutic. SBT8230 is comprised of an ASGR1 monoclonal antibody conjugated to a Toll-like receptor 8 (TLR8) linker-payload. SBT8230 is designed to elicit an anti-viral immune response by targeting TLR8 activation to the liver. SBT8230 antibody designed to recognize an epitope distinct from that bound by the ASGR1 ligand, GalNAc, allowing for possible combination of SBT8230. The Company’s platform enables the strategic pairing of proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites.